Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Trial Profile

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 90010 (Primary)
  • Indications Basal cell cancer; Carcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 13 Jun 2019 Protocol has been amended due to changed in treatment arms .
    • 13 Jun 2019 Planned number of patients changed from 145 to 115.
    • 04 Jun 2019 Results (as of 10 Dec 2018; n=69) assessing safety and tolerability of CC-90010 in patients with advanced solid tumors, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top